<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04448054</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01216-33</org_study_id>
    <nct_id>NCT04448054</nct_id>
  </id_info>
  <brief_title>Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas</brief_title>
  <acronym>ICILOLA</acronym>
  <official_title>Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When patients arrive in the waiting room of the MRI department, patients will be given the&#xD;
      briefing note explaining the purpose of the study and how it is going. During the&#xD;
      consultation, the radiologist will check the inclusion and non-inclusion criteria, and will&#xD;
      take the time to answer all of the patient's questions about the study (or his family member&#xD;
      by telephone if the patient does not is not in a condition to give its consent).&#xD;
&#xD;
      The MRI examination will be performed on a 3T multi-parametric MRI. If the neurological&#xD;
      disorder presented by the patient does not require an injection as part of routine care, only&#xD;
      a high resolution 3D T2 sequence on the nasosinus cavities and the olfactory tract, called&#xD;
      bFFE-Xd for approximately 2 min.&#xD;
&#xD;
      If the neurological disorder presented by the patient requires an injection as part of&#xD;
      current care, the examination will be completed with the nasosinus and olfactory 3D bFFE-Xd&#xD;
      sequence, and the following additional sequences performed after post injection: a&#xD;
&#xD;
        -  3D FABIR 0.9 sequence covering the brain, dedicated to exploring the subarachnoid&#xD;
           spaces;&#xD;
&#xD;
        -  a 3D T1 TSE 0.7 sequence covering the brain looking for meningeal or encephalic contrast&#xD;
           enhancement,&#xD;
&#xD;
        -  FLAIR HR coronal sequence (high resolution) exploring the limbic system.&#xD;
&#xD;
        -  Optional: a 3D FLAIR &quot;labyrinth&quot; sequence in the event of hearing / balance problems; a&#xD;
           DCE infusion sequence (T1-WI) on the olfactory tract if olfactory disorder, which will&#xD;
           be the first sequence made at the time of injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients included with at least one sign of neuromeningeal, neurosensory or neurovascular involvement on MRI imaging with the specific sequences used.</measure>
    <time_frame>baseline</time_frame>
    <description>percentage</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Estimate, With the Contribution of Optimized MRI, the Prevalence of Neurological and Neurovascular Manifestations on Imaging in the Event of SARS-CoV-2</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Case 1: Routine care protocol not requiring injection&#xD;
Realization of the non-injected MRI protocol adapted to the indication&#xD;
+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection&#xD;
Realization of the injected MRI protocol adapted to the indication&#xD;
Before gadolinium injection:&#xD;
Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection&#xD;
After gadolinium injection:&#xD;
Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)&#xD;
FABIR 0.9 3D sequence (+ 4 min)&#xD;
3D sequence T1 TSE 0.7 (+ 2 min 30)&#xD;
FLAIR HR coronal sequence (+ 3 min 30)&#xD;
Option 2: if hearing / balance disorder, adding 3D FLAIR &quot;labyrinth&quot; sequence (+ 6min) which will be the 1st post injection sequence</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient diagnosed with SARS-CoV-2, who should benefit from a brain MRI as part of care for&#xD;
        an acute / chronic neurological disorder.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient&gt; 18 years old Express consent to participate in the study Affiliate or beneficiary&#xD;
        of a social security scheme Patient with suspected SARS-CoV-2 infection in an epidemic&#xD;
        context, confirmed or not by PCR, or close contact with a case confirmed by PCR, typical&#xD;
        chest scanner (non-systematized frosted glass areas predominantly sub-pleural, and at a&#xD;
        later stage of alveolar condensation without excavations, nodules or masses) or positive&#xD;
        serology; Patient to benefit from a brain MRI for an indication within the scope of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient benefiting from a legal protection measure Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amélie YAVCHITZ</last_name>
    <phone>0148036431</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation A De Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie YAVCHITZ</last_name>
      <phone>0148036431</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <investigator>
      <last_name>Guillaume POILLON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

